FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3032378615> ?p ?o ?g. }

• W3032378615 endingPage "553" @default.
• W3032378615 startingPage "553" @default.
• W3032378615 abstract "553 Background: HER2 expression or amplification qualify patients to receive targeted therapeutics against HER2; however, traditional methods of quantifying HER2 amplification using fluorescence in situ hybridization (FISH) do not include a reliable definition for low level amplification. With the promising response rate of patients with low HER2 amplified-metastatic breast cancer to subsequent-line trastuzumab deruxtecan (DS-8201a) therapy, there is a need to improve the existing criteria to accurately identify patients with low HER2. In our study, we investigate whether HER2 amplification quantified by NGS could provide a method to stratify patients into subgroups. Methods: A total of 774 patients diagnosed with breast cancer from Guangdong Provincial People's Hospital (GDPH) who underwent targeted NGS using 520 or 33 cancer-related genes and had their HER2 status evaluated with either FISH or IHC were included in this study. HER2 status were defined as per 2018 ASCO/ACP guidelines. Results: Our results demonstrate that NGS could quantify HER2 amplification with high sensitivity and specificity, with area under the curve of 0.990 [95%CI: 0.982-0.999]. The receiver operating curve indicated an optimal cut-off of 2.62 copy number (CN) for identifying IHC/FISH HER2-negative status with 97.8% specificity. Meanwhile, the cut-off of ≥ 3.62 CN identified patients with IHC/FISH HER2-positive status with 99.8% specificity. Among the 774 patients, 65.8% (n = 509) had HER2 CN of ≤ 2.62 and were classified as HER2 non-amplified, while 25.8% (n = 199) had HER2 CN of ≥ 3.62, classified as HER2-amplified. The remaining 66 patients (8.5%) had HER2 CN between 2.62 and 3.62, and were the patients with heterogeneous IHC/FISH results, classified using NGS as HER2 low-amplified. Patients with low-amplified (49.0% vs. 38.8%, P < 0.001) and amplified (50.3% vs. 38.8%, P < 0.001) HER2 had significantly more number of copy number amplifications in other gene, including CDK12, RARA, and SPOP (P < 0.001, P < 0.001) than patients with HER2 non-amplified, indicating distinct mutation profile. Conclusions: Our results demonstrate that NGS could provide a more accurate stratification of patients based on their HER2 amplification levels. Patients with low levels of HER2 amplification has a distinct mutation profile, suggesting that NGS could serve as a robust tool to identify patients with HER2 amplification, whether high or low, who could benefit treatment with targeted agents designed against heterogeneous HER2 expression." @default.
• W3032378615 created "2020-06-05" @default.
• W3032378615 creator A5001728683 @default.
• W3032378615 creator A5006362016 @default.
• W3032378615 creator A5007270267 @default.
• W3032378615 creator A5008121592 @default.
• W3032378615 creator A5010532818 @default.
• W3032378615 creator A5020858017 @default.
• W3032378615 creator A5024292793 @default.
• W3032378615 creator A5035062653 @default.
• W3032378615 creator A5039378799 @default.
• W3032378615 creator A5041709423 @default.
• W3032378615 creator A5046956504 @default.
• W3032378615 creator A5049407947 @default.
• W3032378615 creator A5050344464 @default.
• W3032378615 creator A5051363890 @default.
• W3032378615 creator A5060809049 @default.
• W3032378615 creator A5062987117 @default.
• W3032378615 creator A5078707584 @default.
• W3032378615 creator A5079524559 @default.
• W3032378615 creator A5088664989 @default.
• W3032378615 creator A5090028444 @default.
• W3032378615 date "2020-05-20" @default.
• W3032378615 modified "2023-10-02" @default.
• W3032378615 title "Next-generation sequencing (NGS) identifies a new breast cancer subtype with HER2 low-amplification status as a candidate for targeted therapy." @default.
• W3032378615 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.553" @default.
• W3032378615 hasPublicationYear "2020" @default.
• W3032378615 type Work @default.
• W3032378615 sameAs 3032378615 @default.
• W3032378615 citedByCount "9" @default.
• W3032378615 countsByYear W30323786152021 @default.
• W3032378615 countsByYear W30323786152022 @default.
• W3032378615 countsByYear W30323786152023 @default.
• W3032378615 crossrefType "journal-article" @default.
• W3032378615 hasAuthorship W3032378615A5001728683 @default.
• W3032378615 hasAuthorship W3032378615A5006362016 @default.
• W3032378615 hasAuthorship W3032378615A5007270267 @default.
• W3032378615 hasAuthorship W3032378615A5008121592 @default.
• W3032378615 hasAuthorship W3032378615A5010532818 @default.
• W3032378615 hasAuthorship W3032378615A5020858017 @default.
• W3032378615 hasAuthorship W3032378615A5024292793 @default.
• W3032378615 hasAuthorship W3032378615A5035062653 @default.
• W3032378615 hasAuthorship W3032378615A5039378799 @default.
• W3032378615 hasAuthorship W3032378615A5041709423 @default.
• W3032378615 hasAuthorship W3032378615A5046956504 @default.
• W3032378615 hasAuthorship W3032378615A5049407947 @default.
• W3032378615 hasAuthorship W3032378615A5050344464 @default.
• W3032378615 hasAuthorship W3032378615A5051363890 @default.
• W3032378615 hasAuthorship W3032378615A5060809049 @default.
• W3032378615 hasAuthorship W3032378615A5062987117 @default.
• W3032378615 hasAuthorship W3032378615A5078707584 @default.
• W3032378615 hasAuthorship W3032378615A5079524559 @default.
• W3032378615 hasAuthorship W3032378615A5088664989 @default.
• W3032378615 hasAuthorship W3032378615A5090028444 @default.
• W3032378615 hasConcept C104317684 @default.
• W3032378615 hasConcept C121608353 @default.
• W3032378615 hasConcept C126322002 @default.
• W3032378615 hasConcept C143998085 @default.
• W3032378615 hasConcept C204232928 @default.
• W3032378615 hasConcept C2777542201 @default.
• W3032378615 hasConcept C2779786085 @default.
• W3032378615 hasConcept C2781230642 @default.
• W3032378615 hasConcept C2909208804 @default.
• W3032378615 hasConcept C30481170 @default.
• W3032378615 hasConcept C505870484 @default.
• W3032378615 hasConcept C530470458 @default.
• W3032378615 hasConcept C54355233 @default.
• W3032378615 hasConcept C71924100 @default.
• W3032378615 hasConcept C7602840 @default.
• W3032378615 hasConcept C86803240 @default.
• W3032378615 hasConceptScore W3032378615C104317684 @default.
• W3032378615 hasConceptScore W3032378615C121608353 @default.
• W3032378615 hasConceptScore W3032378615C126322002 @default.
• W3032378615 hasConceptScore W3032378615C143998085 @default.
• W3032378615 hasConceptScore W3032378615C204232928 @default.
• W3032378615 hasConceptScore W3032378615C2777542201 @default.
• W3032378615 hasConceptScore W3032378615C2779786085 @default.
• W3032378615 hasConceptScore W3032378615C2781230642 @default.
• W3032378615 hasConceptScore W3032378615C2909208804 @default.
• W3032378615 hasConceptScore W3032378615C30481170 @default.
• W3032378615 hasConceptScore W3032378615C505870484 @default.
• W3032378615 hasConceptScore W3032378615C530470458 @default.
• W3032378615 hasConceptScore W3032378615C54355233 @default.
• W3032378615 hasConceptScore W3032378615C71924100 @default.
• W3032378615 hasConceptScore W3032378615C7602840 @default.
• W3032378615 hasConceptScore W3032378615C86803240 @default.
• W3032378615 hasFunder F4320321921 @default.
• W3032378615 hasIssue "15_suppl" @default.
• W3032378615 hasLocation W30323786151 @default.
• W3032378615 hasOpenAccess W3032378615 @default.
• W3032378615 hasPrimaryLocation W30323786151 @default.
• W3032378615 hasRelatedWork W1821649564 @default.
• W3032378615 hasRelatedWork W2105031975 @default.
• W3032378615 hasRelatedWork W2380361820 @default.
• W3032378615 hasRelatedWork W2416082926 @default.
• W3032378615 hasRelatedWork W2443284480 @default.
• W3032378615 hasRelatedWork W2464650279 @default.
• W3032378615 hasRelatedWork W3031174193 @default.

• next